Cargando…
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rhe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640401/ https://www.ncbi.nlm.nih.gov/pubmed/37731083 http://dx.doi.org/10.1007/s10067-023-06769-4 |
_version_ | 1785146623695781888 |
---|---|
author | Papagoras, Charalampos Zioga, Nikoleta Papadopoulos, Vasileios Gerolymatou, Nafsika Kalavri, Eleni Bounos, Christos Simopoulou, Theodora Fragoulis, George E. Panopoulos, Stylianos Fragiadaki, Kalliopi Evangelatos, Gerasimos Bournia, Vasiliki-Kalliopi Arida, Aikaterini Karamanakos, Anastasios Pappa, Maria Kravvariti, Evrydiki Deftereou, Kleopatra Kougkas, Nikolaos Zampeli, Evangelia Kataxaki, Evangelia Melissaropoulos, Konstantinos Barouta, Georgia Panagiotopoulos, Alexandros Koutsianas, Christos Liossis, Stamatis-Nick Georgiou, Panagiotis Dimitroulas, Theodoros Tektonidou, Maria G. Bogdanos, Dimitrios P. Elezoglou, Antonia Voulgari, Paraskevi V. Sfikakis, Petros P. Vassilopoulos, Dimitrios |
author_facet | Papagoras, Charalampos Zioga, Nikoleta Papadopoulos, Vasileios Gerolymatou, Nafsika Kalavri, Eleni Bounos, Christos Simopoulou, Theodora Fragoulis, George E. Panopoulos, Stylianos Fragiadaki, Kalliopi Evangelatos, Gerasimos Bournia, Vasiliki-Kalliopi Arida, Aikaterini Karamanakos, Anastasios Pappa, Maria Kravvariti, Evrydiki Deftereou, Kleopatra Kougkas, Nikolaos Zampeli, Evangelia Kataxaki, Evangelia Melissaropoulos, Konstantinos Barouta, Georgia Panagiotopoulos, Alexandros Koutsianas, Christos Liossis, Stamatis-Nick Georgiou, Panagiotis Dimitroulas, Theodoros Tektonidou, Maria G. Bogdanos, Dimitrios P. Elezoglou, Antonia Voulgari, Paraskevi V. Sfikakis, Petros P. Vassilopoulos, Dimitrios |
author_sort | Papagoras, Charalampos |
collection | PubMed |
description | INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan–Meier curves were used to depict survival data. RESULTS: From August 2020 until June 30, 2022, 456 cases (70.2% females) of COVID-19 with a mean age (± SD) of 51.4 ± 14.0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24.5% and 4%, compared to 12.5% and 0.8% in the vaccinated group (p < 0.001 for both comparisons). The rates of hospitalization for the wild-type, Alpha, Delta, and Omicron periods were 24.7%, 31.3%, 25.9%, and 8.1% respectively (p < 0.0001), while the case fatality rates were 2.7%, 4%, 7%, and 0%, respectively (p = 0.001). Using multivariable regression analysis, factors independently associated with hospitalization were infection by a non-Omicron variant, being non-vaccinated, exposure to rituximab, older age, and respiratory and cardiovascular disease. Independent predictors for death were contracting COVID-19 during the Alpha or Delta period, pulmonary disease, and older age, while being vaccinated was protective. CONCLUSIONS: In this 2-year analysis, the rates of hospitalization and death among patients with SAIRDs have declined significantly. Vaccination and the dominance of the Omicron variant appear to be the major determinants for this shift. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-023-06769-4. |
format | Online Article Text |
id | pubmed-10640401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106404012023-11-14 Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases Papagoras, Charalampos Zioga, Nikoleta Papadopoulos, Vasileios Gerolymatou, Nafsika Kalavri, Eleni Bounos, Christos Simopoulou, Theodora Fragoulis, George E. Panopoulos, Stylianos Fragiadaki, Kalliopi Evangelatos, Gerasimos Bournia, Vasiliki-Kalliopi Arida, Aikaterini Karamanakos, Anastasios Pappa, Maria Kravvariti, Evrydiki Deftereou, Kleopatra Kougkas, Nikolaos Zampeli, Evangelia Kataxaki, Evangelia Melissaropoulos, Konstantinos Barouta, Georgia Panagiotopoulos, Alexandros Koutsianas, Christos Liossis, Stamatis-Nick Georgiou, Panagiotis Dimitroulas, Theodoros Tektonidou, Maria G. Bogdanos, Dimitrios P. Elezoglou, Antonia Voulgari, Paraskevi V. Sfikakis, Petros P. Vassilopoulos, Dimitrios Clin Rheumatol Original Article INTRODUCTION: This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). METHODS: Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan–Meier curves were used to depict survival data. RESULTS: From August 2020 until June 30, 2022, 456 cases (70.2% females) of COVID-19 with a mean age (± SD) of 51.4 ± 14.0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24.5% and 4%, compared to 12.5% and 0.8% in the vaccinated group (p < 0.001 for both comparisons). The rates of hospitalization for the wild-type, Alpha, Delta, and Omicron periods were 24.7%, 31.3%, 25.9%, and 8.1% respectively (p < 0.0001), while the case fatality rates were 2.7%, 4%, 7%, and 0%, respectively (p = 0.001). Using multivariable regression analysis, factors independently associated with hospitalization were infection by a non-Omicron variant, being non-vaccinated, exposure to rituximab, older age, and respiratory and cardiovascular disease. Independent predictors for death were contracting COVID-19 during the Alpha or Delta period, pulmonary disease, and older age, while being vaccinated was protective. CONCLUSIONS: In this 2-year analysis, the rates of hospitalization and death among patients with SAIRDs have declined significantly. Vaccination and the dominance of the Omicron variant appear to be the major determinants for this shift. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10067-023-06769-4. Springer International Publishing 2023-09-21 2023 /pmc/articles/PMC10640401/ /pubmed/37731083 http://dx.doi.org/10.1007/s10067-023-06769-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Papagoras, Charalampos Zioga, Nikoleta Papadopoulos, Vasileios Gerolymatou, Nafsika Kalavri, Eleni Bounos, Christos Simopoulou, Theodora Fragoulis, George E. Panopoulos, Stylianos Fragiadaki, Kalliopi Evangelatos, Gerasimos Bournia, Vasiliki-Kalliopi Arida, Aikaterini Karamanakos, Anastasios Pappa, Maria Kravvariti, Evrydiki Deftereou, Kleopatra Kougkas, Nikolaos Zampeli, Evangelia Kataxaki, Evangelia Melissaropoulos, Konstantinos Barouta, Georgia Panagiotopoulos, Alexandros Koutsianas, Christos Liossis, Stamatis-Nick Georgiou, Panagiotis Dimitroulas, Theodoros Tektonidou, Maria G. Bogdanos, Dimitrios P. Elezoglou, Antonia Voulgari, Paraskevi V. Sfikakis, Petros P. Vassilopoulos, Dimitrios Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title | Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title_full | Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title_fullStr | Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title_full_unstemmed | Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title_short | Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases |
title_sort | omicron variant dominance and anti-sars-cov-2 vaccination are key determinants for a milder course of covid-19 in patients with systemic autoimmune rheumatic diseases |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640401/ https://www.ncbi.nlm.nih.gov/pubmed/37731083 http://dx.doi.org/10.1007/s10067-023-06769-4 |
work_keys_str_mv | AT papagorascharalampos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT zioganikoleta omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT papadopoulosvasileios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT gerolymatounafsika omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT kalavrieleni omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT bounoschristos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT simopouloutheodora omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT fragoulisgeorgee omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT panopoulosstylianos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT fragiadakikalliopi omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT evangelatosgerasimos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT bourniavasilikikalliopi omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT aridaaikaterini omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT karamanakosanastasios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT pappamaria omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT kravvaritievrydiki omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT deftereoukleopatra omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT kougkasnikolaos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT zampelievangelia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT kataxakievangelia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT melissaropouloskonstantinos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT baroutageorgia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT panagiotopoulosalexandros omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT koutsianaschristos omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT liossisstamatisnick omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT georgioupanagiotis omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT dimitroulastheodoros omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT tektonidoumariag omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT bogdanosdimitriosp omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT elezoglouantonia omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT voulgariparaskeviv omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT sfikakispetrosp omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases AT vassilopoulosdimitrios omicronvariantdominanceandantisarscov2vaccinationarekeydeterminantsforamildercourseofcovid19inpatientswithsystemicautoimmunerheumaticdiseases |